Dabigatran Etexilate Capsules, 75 mg recall — Ascend Laboratories, LLC (Class III)

Ascend Laboratories, LLC is recorded by the U.S. Food and Drug Administration (FDA) as recalling Dabigatran Etexilate Capsules, 75 mg — a Class III recall, initiated 2026-07-16 and posted to the FDA enforcement report on 2026-08-05, under recall number D-0738-2026. Status Ongoing, with no termination date on the record. The reason the FDA record carries is, verbatim: “Failed impurity/degradation specification: an OOS result observed in Related substance test analysis w.r.t Impurity II, Impurity III and Total impurities for 12-month stability”. From the product description, the form is capsules, the strength given is 75 mg, the package is described as 60-count (6x10)blister pack and it is marked Rx only. 1 National Drug Code number is printed in the record: 0904-7253-68. Distribution is recorded as “USA Nationwide” — Nationwide (US), with the recalling firm on record in NJ, United States. The FDA files it under event ID 99421 together with 2 other recall numbers, all listed and linked below. Within that event this is the strength 75 mg, package 60-count (6x10)blister pack and ndc 0904-7253-68 configuration; the sibling records differ on strength, package and ndc and match on everything else the source states. Values are reproduced from the linked openFDA report; regulatory information, not medical advice.

Regulatory snapshot

Recall number D-0738-2026
FDA event ID 99421 (3 recall numbers)
Classification Class III (least serious regulatory tier)
Status Ongoing
Recalling firm Ascend Laboratories, LLC
Recall initiated 2026-07-16
Reported by FDA 2026-08-05
Report lag 20 days from initiation to report
Distribution USA Nationwide — Nationwide (US)
Firm location on record NJ, United States
Product description (source) Dabigatran Etexilate Capsules, 75 mg, 60-count (6x10)blister pack further packaged in a carton, Rx only, Manufactured by: Alkem Laboratories Ltd., Mumbai, INDIA, Distributed by: MAJOR PHARMACEUTICALS, Indianapolis, IN 46268, NDC 0904-7253-68.

Reason reported by FDA

Failed impurity/degradation specification: an OOS result observed in Related substance test analysis w.r.t Impurity II, Impurity III and Total impurities for 12-month stability

23 words from the enforcement report field reason_for_recall, reproduced without edit — the firm's own wording, not an assessment.

Product identifiers in this record

7 identifying values matched by exact pattern in the 31-word product description above; each is a literal substring of it.

Product named Dabigatran Etexilate Capsules
Form Capsules
Strength 75 mg
Package 60-count (6x10)blister pack
NDC 0904-7253-68
Marketing category Rx only
Manufactured by Alkem Laboratories Ltd., Mumbai
Distributed by MAJOR PHARMACEUTICALS, Indianapolis

Which configuration this record is

3 recall numbers share event 99421. They differ on strength, package and ndc and agree on everything else the source states, so those are the values to check a package against.

Attribute This record (D-0738-2026) D-0737-2026D-0739-2026
Strength 75 mg 150 mg75 mg
Package 60-count (6x10)blister pack 60-count (6x10) blister pack30-count (3x10) blister pack
NDC 0904-7253-68 0904-7255-680904-7253-04

Shared across all 3 records under this event: form Capsules; product named Dabigatran Etexilate Capsules; fda tier Class III; recalling firm Ascend Laboratories, LLC; the same reason text; initiated 2026-07-16; reported 2026-08-05.

Event context: 3 recall numbers under event 99421

One enforcement action, 3 recall numbers: the FDA filed 2 further configurations of this action under event 99421. Each keeps its own recall number and dates.

Recall recordRecall numberFDA tierStrength / formNDCReported
Dabigatran Etexilate Capsules, 150 mgD-0737-2026Class III150 mg · Capsules0904-7255-682026-08-05
Dabigatran Etexilate Capsules, 75 mgD-0739-2026Class III75 mg · Capsules0904-7253-042026-08-05

Other indexed recalls from Ascend Laboratories, LLC

9 indexed records name Ascend Laboratories, LLC as the recalling firm, across 6 FDA events, reported 2026-05-20 to 2026-08-05. A coverage-limited activity count over the ingested window, not a quality rating.

Recall recordRecall numberFDA tierStrength / formReported
Amlodipine and Olmesartan Medoxomil Tablets, 10 mg/20 mgD-0712-2026Class II10 mg/20 mg · Tablets2026-07-29
Dabigatran etexilate Capsules, 110 mgD-0735-2026Class III110 mg · Capsules2026-07-29
Dabigatran etexilate Capsules, 150 mgD-0736-2026Class III150 mg · Capsules2026-07-29
Minocycline Hydrochloride Extended-Release Tablets, 115 mgD-0597-2026Class II115 mg · Extended-Release Tablets2026-06-17
Amlodipine and Olmesartan Medoxomil Tablets, 5mg/40mgD-0556-2026Class II5mg/40mg · Tablets2026-06-10
Ascend Laboratories, 25 mgD-0547-2026Class II25 mg · Extended-Release Tablets2026-05-20

Reported in the same month (2026-08)

11 enforcement reports carry a report date in 2026-08; these 1 are the Class III ones nearest this record.

Recall recordRecall numberRecalling firmFDA tierReported
Total Parental Nutrition - Pediatric PN Patient-Specific TPN Bag, 416.8 mLD-0740-2026Central Admixture Pharmacy Services IncClass III2026-08-12

Nearest Class III recalls by date

25 of 250 indexed records share the Class III tier; the 7 nearest to 2026-08-05 by report date are listed here.

Recall recordRecall numberRecalling firmStrength / formReported
Lidolog Kit, 2%D-0713-2026Asclemed Usa Inc.2% · Injection2026-07-29
Fexofenadine Hydrochloride Tablets, 180 mgD-0654-2026Sun Pharmaceutical Industries Inc180 mg · Tablets2026-07-08
hydrOXYzine Hydrochloride Oral Solution, 10 mg/5 mLD-0619-2026Ani Pharmaceuticals, Inc.10 mg/5 mL · Oral Solution2026-07-01
Focalin XR (dexmethylphenidate HCl) 5 mgD-0608-2026Sandoz Inc5 mg · Extended-Release Capsules2026-06-24
Epinephrine Injection, 1mg/mLD-0581-2026Fresenius Kabi Usa, LLC1mg/mL · Injection2026-06-17
Primidone Tablets, 50 mgD-0585-2026Amneal Pharmaceuticals, LLC50 mg · Tablets2026-06-17
Lidocaine HCl Injection, 2%D-0552-2026Eugia US LLC2% · Injection2026-06-10

Reading this record

Class III is the FDA's own severity tier for the recall action — 25 of the 250 indexed records carry it — and it describes the agency's assessment of the action, not a risk statement about any individual. A search on event 99421 returns all 3 of these recall numbers; a search on D-0738-2026 returns only this configuration. Match a package against 0904-7253-68 at the FDA source to confirm it is covered.

Namespace context: the Class III index (25 records) and the recall hub (250 records, 118 FDA events); Ascend Laboratories, LLC (9 indexed records) aggregates this firm across datasets.

Coverage and limits of this record

This page reflects the openFDA enforcement report for D-0738-2026 as ingested on 2026-08-22, which can lag the live FDA record and omits detail held only in primary documents. It offers no clinical assessment, no advice about whether to use any product, and no substitute. For any health question consult a qualified healthcare professional.

Source & provenance

Official source
https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0738-2026%22
Source dataset
openFDA Drug Enforcement API
Publication date
2026-08-05
Ingested
2026-08-22
Record hash
b3cbbcaf545b4935

Verify every value against the official FDA source above. This site links to the regulator's record rather than replacing it.